ArticleACS omega2025
Danhong Injection Inhibits Apoptosis in Ischemia/Reperfusion Injury Based on Network Pharmacology Analysis, Molecular Docking, and Experimental Verification.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computational-experimental identification of bioactive component combinations from Salvia miltiorrhiza for cardiovascular protection.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Medication stewardship by clinical pharmacists in acute ischemic stroke care: a retrospective analysis of drug-related problem reduction and cost-saving outcomes.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Danhong injection (DHI), a Chinese patent compound injection, is widely used in the treatment of cardiovascular diseases (CVD) in China. However, the underlying mechanisms have not been fully elucidated. This study investigated the therapeutic effect and the underlying mechanisms of DHI against ischemia-reperfusion (I/R) injury and endothelial dysfunction (ED). Network pharmacology analysis revealed that DHI had six core active compounds (Danshensu, salvianolic acid A, salvianolic acid B, rosmarinic acid, protocatechualdehyde, and caffeic acid) and 19 potential targets in treating I/R injury. Notably, the regulation of apoptosis was significantly enriched, as indicated by the results of the gene ontology (GO) enrichment analysis. Molecular docking studies confirmed that these targets had high affinity with the active compounds of DHI. Finally, experimental validation in vivo and in vitro demonstrated that DHI could mitigate I/R injury and ED, potentially by reducing oxidative damage through the inhibition of apoptosis via the PTEN/AKT pathway. These findings significantly advance our understanding of the molecular mechanisms in DHI treatment and contribute further to promoting the clinical application of CVD.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.